Longitudinal Drug Studies in People with Dementia: Ethical Challenges in Assessing Capacity and Get
Harvard Research Ethics Consortium, Harvard Medical School
Deadline: September 18, 2015
"Longitudinal Drug Studies in People with Dementia: Ethical Challenges in Assessing Capacity and Getting Consent"
Friday September 18, 2015 from 12:30 PM to 2:00 PM EDT
Harvard Medical School, Countway Library, Ballard Room, 5th Floor, 10 Shattuck St, Boston, MA 02115,
How and when should you get consent from patients with Alzheimer's disease to participate in longitudinal drug studies? The Center for Alzheimer Research and Treatment (CART), affiliated with the Department of Neurology at Brigham and Women's Hospital, has several interventional studies to treat people with mild-to-moderate Alzheimer's disease and mild cognitive impairment.
Major challenges include assessing the participant's capacity to participate in a drug study, and, in longitudinal studies, handling ongoing disclosure of new risks as participants' capacity to consent diminishes.
Research protocols that raise this ethical issue will be presented by Seth Gale MD, Associate Neurologist at BWH, and Alison Pietras, Research Coordinator at CART. Melissa Frumin MD, a neuropsychiatrist at BWH and an IRB Chair at the Partners Human Research Committee will describe ethical concerns addressed during the review process. Emily Chi Fogler JD Counsel at Verrill Dana and former Senior Legal Counsel at Partners HealthCare System will be our commentator.
RSVP by Wednesday, September 16th.
If you have any questions about the event or how to RSVP, please contact Toni Tugenberg at email@example.com subjects research opportunity research